Increment of in vivo binding of [3H]SCH 23390, a dopamine D1 receptor ligand, induced by cyclic AMP-dependent protein kinase in rat brain

Brain Research

Volumn 952, Issue 2, 2002, Pages 211-217

  Abe, Kohji ^a,b   Hosoi, Rie ^a   Momosaki, Sotaro ^a   Kobayashi, Kaoru ^a   Ibii, Nobuhiro ^b   Inoue, Osamu ^a  

^a OSAKA UNIVERSITY   (Japan)

^b SHIONOGI AND CO LTD   (Japan)

Author keywords

cAMP; Dopamine D1 receptor; In vivo 3H SCH 23390 receptor binding; Protein kinase A; Rat brain

Indexed keywords

8 BROMO CYCLIC AMP; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; CYCLIC AMP DERIVATIVE; DOPAMINE 1 RECEPTOR; N 6,2' O DIBUTYRYL CYCLIC ADENOSINE PHOSPHATE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BINDING SITE; CENTRAL NERVOUS SYSTEM; CONSCIOUSNESS; CONTROLLED STUDY; CORPUS STRIATUM; DRUG BINDING; IN VITRO STUDY; IN VIVO STUDY; KINETICS; MALE; MOLECULAR BIOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RAT; RECEPTOR BINDING; REGULATORY MECHANISM;

(R)-2,3,4,5-TETRAHYDRO-8-CHLORO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL; 8-BROMO CYCLIC ADENOSINE MONOPHOSPHATE; ANIMALS; BINDING, COMPETITIVE; BRAIN; BUCLADESINE; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DOPAMINE ANTAGONISTS; ENZYME INHIBITORS; MALE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D1;

EID: 0037131084     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(02)03194-3     Document Type: Article

References (25)

1. +-ATPase activity in renal tubule cells. Proc. Natl. Acad. Sci. USA. 88:1991;2798-2801.
2. 11C]raclopride binding with continuous infusion. J. Cereb. Blood Flow Metab. 17:1997;437-447.
3. Chou Y.H., Karlsson P., Halldin C., Olsson H., Farde L. A PET study of D1-like dopamine receptor ligand binding during altered endogenous dopamine levels in the primate brain. Psychopharmacology. 146:1999;220-227.
4. 3H]spiperone binding: evidence for accumulation in corpus striatum by agonist-mediated receptor internalization. J. Cereb. Blood Flow Metab. 8:1988;291-303.
5. Dewey S.L., Smith G.S., Logan J., Brodie J.D., Fowler J.S., Wolf A.P. Striatal binding of the PET ligand 11C-raclopride is altered by drugs that modify synaptic dopamine levels. Synapse. 13:1993;350-356.
6. Dumartin B., Caille I., Gonon F., Bloch B. Internalization of D1 dopamine receptor in striatal neurons in vivo as evidence of activation by dopamine agonists. J. Neurosci. 18:1998;1650-1661.
7. Hartvig P., Torstenson R., Tedroff J., Watanabe Y., Fasth K.J., Bjurling P., Langstorm B. Amphetamine effects on dopamine release and synthesis rate studied in the Rhesus monkey brain by positron emission tomography. J. Neural Transm. 104:1997;329-339.
8. Inoue O., Kobayashi K., Gee A. Changes in apparent rates of receptor binding in the intact brain in relation to the heterogeneity of reaction environments. Crit. Rev. Neurobiol. 13:1999;199-225.
9. 3H]N-methylspiperone. Neuropharmacology. 30:1991;1101-1106.
10. Insel T.R. Decreased in vivo binding to brain benzodiazepine receptors during social isolation. Psychopharmacology. 97:1989;142-144.
11. Jiang D., Sibley D.R. Regulation of D1 dopamine receptors with mutations of protein kinase phosphorylation sites: Attenuation of the rate of agonist-induced desensitization. Mol. Pharmacol. 56:1999;675-683.
12. 3H]SCH 23390 induced by MK-801 in the mouse striatum. Neuropharmacology. 32:1993;341-348.
13. Laruelle M. Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J. Cereb. Blood Flow Metab. 20:2000;423-451.
14. Ofori S., Bugnon O., Schorderet M. Agonist-induced desensitization of dopamine D-1 receptors in bovine retina and rat striatum. J. Pharmacol. Exp. Ther. 266:1993;350-357.
15. Patlak C.S., Blasberg R.G., Fenstermacher J.D. Graphical evaluation of blood-to-brain transfer constants form multiple-time uptake data. J. Cereb. Blood Flow Metab. 3:1983;1-7.
16. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates. 1986;Academic Press, New York.
17. Price C.J., Kim P., Raymond L.A. D1 dopamine receptor-induced cyclic AMP-dependent protein kinase phosphorylation and potentiation of striatal glutamate receptors. J. Neurochem. 73:1999;2441-2446.
18. Santiago M., Westerink B.H.C. Role of adenylate cyclase in the modulation of the release of dopamine: a microdialysis study in the striatum of the rat. J. Neurochem. 55:1990;169-174.
19. Suhara T., Inoue O., Kobayashi K. Effect of desipramine on dopamine receptor binding in vivo. Life Sci. 47:1990;2119-2126.
20. Stoof J.C., Kebabian J.W. Opposing roles for D1 and D2 dopamine receptors in efflux of cyclic AMP from rat neostriatum. Nature. 294:1981;366-368.
21. Suyama K., Dykstra K.H., Masana M.I., Manji H.K., Potter W.Z. In vivo evidence that nonneuronal β-adrenoceptors as well as dopamine receptors contribute to cyclic AMP efflux in rat striatum. J. Neurochem. 62:1994;1734-1740.
22. Surmeier D.J., Bargas J., Hemmings H.C. Jr., Nairn A.C., Greengard P. Modulation of calcium currents by a D1 dopaminergic protein kinase/phosphatase cascade in rat neostriatal neurons. Neuron. 14:1995;385-397.
23. Ventura A.L.M., Sibley D.R. Altered regulation of D1 dopamine receptor in mutant chinese hamster ovary cells deficient in cyclic AMP-dependent protein kinase activity. J. Pharmacol. Exp. Ther. 293:2000;426-434.
24. Weizman R., Weizman A., Kook K.A., Vocci F., Deutsch S.L., Paul S.M. Repeated swim stress alters brain benzodiazepine receptors measured in vivo. J. Pharmacol. Exp. Ther. 249:1989;701-707.
25. Zhou X.M., Sidhu A., Fishman P.H. Desensitization of the human D1 dopamine receptor: evidence for involvement of both cyclic AMP-dependent and receptor-specific protein kinases. Mol. Cell. Neurosci. 2:1991;464-472.